Year-end Sale % OFF 
Abstract
Drugs like chloroquine (CQ)/ Hydroxy chloroquine (HCQ) had been widely used as treatment options at the start of pandemic with little supporting evidence. American Thoracic Society (ATS) led International Task Force had come up with some important `suggestions’ regarding CQ/ HCQ usage initially. They have suggested to use these drugs in covid 19 patients with severe pneumonia on a case by case basis. However, the role of HCQ prophylaxis, the effect of combination with macrolides, benefit versus risk assessment, age group profile and the exact definition of severe pneumonia remain unanswered among others. Now, it had become quite obvious that our perceptions based on some observational studies were completely wrong.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
